We’re beating heart disease

The FDA has approved the first pill to replace injections for fighting high cholesterol. The drug, enlicitide, is an oral PCSK9 inhibitor. It lowers LDL cholesterol levels by nearly 60%, according to the Times of India, Healthline, and Harvard Health. The New York Times and Medscape note that this approval could significantly alter how primary care physicians manage cholesterol. The drug's approval follows extensive clinical trials.

The Times of India, Healthline, and Harvard Health all note that enlicitide reduces LDL cholesterol levels by more than half. The New York Times and Medscape discuss the potential impact on primary care, suggesting that the pill could make cholesterol management more accessible and convenient. ABC11 News features a patient from the Raleigh area who is hopeful about the new treatment. The drug's approval is not without controversy. A cardiologist quoted in STAT expresses skepticism about whether enlicitide is a true game-changer.

The article does not specify the reasons for this skepticism. Vox.com frames the approval as part of a broader trend in beating heart disease, but does not specify what other developments are contributing to this trend. The FDA's approval of enlicitide marks a significant shift in cholesterol management. However, the drug's long-term effectiveness and impact on heart disease remain subjects of debate. Patients and healthcare providers will be watching closely to see how this new treatment performs in real-world settings.